Starling Oncology, Inc. is a healthcare company focused on providing specialized cancer care through a value-based, community-oriented model. Founded in 2007 and formerly known as The Oncology Institute, the company operates oncology practices designed to bring cancer treatment closer to patients while coordinating care across physicians, clinics, insurers and other healthcare providers. Its network serves a large patient population across multiple states, with both company-affiliated and independent oncology providers participating in its broader platform.
The company's services extend well beyond conventional physician appointments. Starling Oncology operates cancer treatment and infusion centers where patients can receive chemotherapy, immunotherapy and other oncology treatments, while also providing laboratory testing, outpatient blood transfusions, in-house pharmacy services, clinical trials, financial counseling and end-of-life support. This combination allows many aspects of cancer treatment and supportive care to be coordinated through the same community-based network rather than requiring patients to rely entirely on separate facilities and providers.
Technology and care coordination have become increasingly important components of Starling Oncology's business. The company has developed Starling Nexus, a proprietary platform intended to bring clinical decision support, evidence-based treatment pathways, ancillary services and insurance authorization workflows into a unified system. The platform is designed for use by oncology providers and health plans as well as to support patients, with the broader objective of reducing administrative friction and helping physicians follow established treatment pathways while managing the complexity and cost associated with cancer care.
Starling Oncology's business model is built around value-based oncology, in which the company works with health plans and provider networks to manage cancer care for defined patient populations rather than relying solely on traditional fee-for-service arrangements. Its operations include affiliated community oncology practices as well as larger physician networks, giving the company a role that extends beyond operating individual clinics into managing oncology care across an interconnected provider platform. The company trades on the Nasdaq under the ticker STLN, following its transition from The Oncology Institute to the Starling Oncology name.